Search Results

You are looking at 131 - 140 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered

David S. Ettinger

gastrointestinal system, they include nausea, emesis, diarrhea, colitis, perforation, and pancreatitis. Neurologic adverse events include neuropathy, meningitis, and Guillain-Barré syndrome; ocular events include iritis, uveitis, and conjunctivitis; cardiac events

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

standard oncology definitions used, suggesting that the actual response rates may be higher for both of these groups than reported. To improve the tolerance of clinical side effects such as muscle spasms, fatigue, anorexia, nausea, and taste changes

Full access

Sexual Function in Cancer Survivors: Updates to the NCCN Guidelines for Survivorship

Michelle E. Melisko and Joseph B. Narus

is taken every day, and in clinical trials side effects included substantial dizziness, somnolence, nausea, and fatigue.” Treatment Alternatives for Men Dr. Narus reviewed some of the types of symptoms that may interfere with sexual function

Full access

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass

, constipation, and/or nausea/emesis. 12 Intrathoracic masses can cause coughing, dyspnea, wheezing, stridor, chest pain, and/or reduced endurance. Tumors in the head and neck may be associated with swollen glands; swelling in the neck, jaw, gingival area, or

Full access

Management of Central Nervous System Tumors

Thomas Kaley and Louis B. Nabors

, hydrocephalus, and nausea/vomiting. Specific symptoms include weakness in the extremities, visual changes, hearing loss, and inattention. 1 Diagnosis is performed using CT and MRI. Management is typically conservative, with surgery, radiation, and chemotherapy

Full access

A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

2 woman presented at 8 weeks gestation to a community hospital with abdominal pain, nausea, and vomiting. She reported that her symptoms had started 6 months earlier with the sensation of abdominal fullness. She had no prior medical or surgical

Full access

Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan

Navika D. Shukla, Ryan S. Chiang, and Alexander D. Colevas

tolerated the drug well; adverse effects from infusion included transient fatigue and grade 1 nausea, vomiting, and gastroparesis. Figure 1. Progression of metastatic disease on ado-trastuzumab emtansine (right) followed by complete resolution of FDG

Full access

Palliative Care

Michael H. Levy, Anthony Back, Costantino Benedetti, J. Andrew Billings, Susan Block, Barry Boston, Eduardo Bruera, Sydney Dy, Catherine Eberle, Kathleen M. Foley, Sloan Beth Karver, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, David Spiegel, Linda Sutton, Susan Urba, Jamie H. Von Roenn, and Sharon M. Weinstein

. Chemotherapy-induced nausea and vomiting: state of the art in 2006 . J Support Oncol 2006 ; 4 ( 2 Suppl 1 ): 3 – 8 . 52 Becker G Galandi D Blum HE . Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a

Full access

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

abemaciclib differs from that of palbociclib and ribociclib. In this study, most frequent adverse events were diarrhea, fatigue, nausea, and neutropenia. Several trials are also studying the utility of combining CDK 4/6 inhibitors with other types of ET. The

Full access

Updates in the Treatment of Metastatic Urothelial Cancer

Presented by: Thomas W. Flaig

.4 months (95% CI, 3.5–7.2 months), a median OS of 10.9 months (95% CI, 9.0–13.8 months), and a response rate of 27%. Treatment-related side effects included hypersensitivity reactions, nausea, vomiting, diarrhea, and bone marrow suppression. Of note, Dr